Journal article

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates

  • Testa, Raymond AstraZeneca Pharmaceuticals LP, Waltham, MA, USA
  • Cantón, Rafael Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, Spain
  • Giani, Tommaso Department of Medical Technologies, University of Siena, Italy
  • Morosini, María-Isabel Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Biomédica (IRYCIS), Madrid, Spain
  • Nichols, Wright W. AstraZeneca Pharmaceuticals LP, Waltham, MA, USA
  • Seifert, Harald German Centre for Infection Research (DZIF), Bonn-Cologne, Germany - Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany
  • Stefanik, Danuta Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany
  • Rossolini, Gian Maria Department of Medical Technologies, University of Siena, Italy - Department of Experimental and Clinical Medicine, University of Florence, Italy - Clinical Microbiology Unit, Florence Careggi University Hospital, Fllorence, Italy
  • Nordmann, Patrice Medical and Molecular Microbiology Unit, University of Fribourg, Switzerland - INSERM Research Unit, Hospital Bicêtre, South-Paris University, Paris, France
Show more…
    17.02.2015
Published in:
  • International Journal of Antimicrobial Agents. - 2015, vol. 45, no. 6, p. 641–646
English Recent clinical isolates of key Gram-negative and Gram-positive bacteria were collected in 2012 from hospitalised patients in medical centres in four European countries (France, Germany, Italy and Spain) and were tested using standard broth microdilution methodology to assess the impact of 4 mg/L avibactam on the in vitro activities of ceftazidime, ceftaroline and aztreonam. Against Enterobacteriaceae, addition of avibactam significantly enhanced the level of activity of these antimicrobials. MIC90 values (minimum inhibitory concentration that inhibits 90% of the isolates) of ceftazidime, ceftaroline and aztreonam for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Morganella morganii were reduced up to 128-fold or greater when combined with avibactam. A two-fold reduction in the MIC90 of ceftazidime to 8 mg/L was noted in Pseudomonas aeruginosa isolates when combined with avibactam, whereas little effect of avibactam was noted on the MIC values of the test compounds when tested against Acinetobacter baumannii isolates. Avibactam had little effect on the excellent activity of ceftazidime, ceftaroline and aztreonam against Haemophilus influenzae. It had no impact on the in vitro activity of ceftazidime and ceftaroline against staphylococci and streptococci. This study demonstrates that addition of avibactam enhances the activities of ceftazidime, ceftaroline and aztreonam against Enterobacteriaceae and P. aeruginosa but not against A. baumannii.
Faculty
Faculté des sciences et de médecine
Department
Médecine 3ème année
Language
  • English
Classification
Biology
License
License undefined
Identifiers
Persistent URL
https://folia.unifr.ch/unifr/documents/304505
Statistics

Document views: 5 File downloads:
  • nor_vac.pdf: 2